The efficacy of immune checkpoint inhibitors has been widely recognized for their efficacy in cancer treatment, but the response rate is not high, and patients with programmed cell death protein 1 (PD-1) resistance make tumor treatment more difficult. This evidence concerns the gene PDCD1 and neoplasm.